[
  {
    "ts": null,
    "headline": "NRG Energy, Amgen, Arista Networks: Trending Tickers",
    "summary": "NRG Energy (NRG) stock falls after its 295MW Texas data center deal underwhelmed investors. Amgen (AMGN) stock dips as investors focus on uncertainties around its obesity drug, MariTide, despite a second quarter beat. Arista Networks (ANET) hits record highs after strong second quarter results and an upbeat third quarter forecast. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
    "url": "https://finnhub.io/api/news?id=ef5d0a77d21eab9cf161aa04cb759b5507e79e7f465ea58b6f6b519895eb372e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754510508,
      "headline": "NRG Energy, Amgen, Arista Networks: Trending Tickers",
      "id": 136240896,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "NRG Energy (NRG) stock falls after its 295MW Texas data center deal underwhelmed investors. Amgen (AMGN) stock dips as investors focus on uncertainties around its obesity drug, MariTide, despite a second quarter beat. Arista Networks (ANET) hits record highs after strong second quarter results and an upbeat third quarter forecast. To watch more expert insights and analysis on the latest market action, check out more Market Domination here.",
      "url": "https://finnhub.io/api/news?id=ef5d0a77d21eab9cf161aa04cb759b5507e79e7f465ea58b6f6b519895eb372e"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Stock Sinks As Market Eyes MariTide's Next Move",
    "summary": "Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 billion. Also Read: RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program Product sales gr",
    "url": "https://finnhub.io/api/news?id=3a64b35ab110a54f303532f52ee2a561aa138057c37a37030f84a46476d5bbf9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754504341,
      "headline": "Amgen Stock Sinks As Market Eyes MariTide's Next Move",
      "id": 136240897,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) shares are trading lower on Wednesday, despite the company reporting second-quarter results that surpassed analyst expectations after markets closed on Tuesday. The US drug maker reported adjusted earnings of $6.02 per share, up 21% year over year, beating the consensus of $5.24. Amgen reported quarterly sales of $9.18 billion, up 9%, beating the Wall Street estimate of $8.87 billion. Also Read: RFK Jr. Sued By Eli Lilly, Amgen Over Drug Discount Program Product sales gr",
      "url": "https://finnhub.io/api/news?id=3a64b35ab110a54f303532f52ee2a561aa138057c37a37030f84a46476d5bbf9"
    }
  },
  {
    "ts": null,
    "headline": "Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter",
    "summary": "Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.",
    "url": "https://finnhub.io/api/news?id=dd29639d0238ca3d4644500bd61f55b1239df8c9ca47c16f931743628df6f0b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754500706,
      "headline": "Why S&P 500 Stock Amgen Stumbled Despite Its Beat-And-Raise Quarter",
      "id": 136239125,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen stock dropped Wednesday despite a strong second quarter as investors look ahead to the next weight-loss readouts.",
      "url": "https://finnhub.io/api/news?id=dd29639d0238ca3d4644500bd61f55b1239df8c9ca47c16f931743628df6f0b1"
    }
  },
  {
    "ts": null,
    "headline": "Teva’s Ajovy becomes first migraine prevention drug approved for children",
    "summary": "With the label expansion, Teva gains an edge over rivals Amgen and Eli Lilly in the CGRP inhibitor arena.",
    "url": "https://finnhub.io/api/news?id=ab3512f7c3134c2a221a6d3c2d814e7540c1e8f26a7255d535079374b9cdd34b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754499497,
      "headline": "Teva’s Ajovy becomes first migraine prevention drug approved for children",
      "id": 136239126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "With the label expansion, Teva gains an edge over rivals Amgen and Eli Lilly in the CGRP inhibitor arena.",
      "url": "https://finnhub.io/api/news?id=ab3512f7c3134c2a221a6d3c2d814e7540c1e8f26a7255d535079374b9cdd34b"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=2bd7c7710d6583dcb00b33d5116641eb58703e64811d27ed4952a390510de153",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754498100,
      "headline": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
      "id": 136251682,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=2bd7c7710d6583dcb00b33d5116641eb58703e64811d27ed4952a390510de153"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Edges Up As Fed Officials Signal Shifts; Nvidia Rival Dives On Earnings (Live Coverage)",
    "summary": "The Dow Jones index fell modestly Wednesday, but Nvidia rival Advanced Micro Devices plunged on earnings.",
    "url": "https://finnhub.io/api/news?id=f57fb75e5764747813b15caec127595e5643b38f9259915151c8154c4e2b69a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754491940,
      "headline": "Stock Market Today: Dow Edges Up As Fed Officials Signal Shifts; Nvidia Rival Dives On Earnings (Live Coverage)",
      "id": 136237052,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The Dow Jones index fell modestly Wednesday, but Nvidia rival Advanced Micro Devices plunged on earnings.",
      "url": "https://finnhub.io/api/news?id=f57fb75e5764747813b15caec127595e5643b38f9259915151c8154c4e2b69a3"
    }
  },
  {
    "ts": null,
    "headline": "Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly",
    "summary": "Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.",
    "url": "https://finnhub.io/api/news?id=b46ba3b9300f7d308adca484ee62121596ed365da9fd22cf49eced07e30fed88",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754488260,
      "headline": "Amgen's Q2 Earnings & Sales Beat Estimates, 2025 View Raised Slightly",
      "id": 136238310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen posts strong Q2 beats on earnings and sales, driven by double-digit drug volume gains.",
      "url": "https://finnhub.io/api/news?id=b46ba3b9300f7d308adca484ee62121596ed365da9fd22cf49eced07e30fed88"
    }
  },
  {
    "ts": null,
    "headline": "Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators",
    "summary": "As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for year",
    "url": "https://finnhub.io/api/news?id=7aaa048402f4cf4ad178b02743952d18885a5c4f9f336b7cfb6e299e970c4dc9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754483400,
      "headline": "Clinical Progress in Rare Disease Signals Long-Term Revenue Potential for Innovators",
      "id": 136237331,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "As the American population gets older, chronic and rare diseases are becoming a significant healthcare issue, particularly for older adults. The aging population's increasing life expectancy also leads to more complex healthcare needs, especially for conditions that are both chronic and difficult to diagnose. Many of these rare conditions lack FDA-approved treatments, and their symptoms in seniors are frequently mistaken for normal signs of aging, causing diagnostic delays that can last for year",
      "url": "https://finnhub.io/api/news?id=7aaa048402f4cf4ad178b02743952d18885a5c4f9f336b7cfb6e299e970c4dc9"
    }
  },
  {
    "ts": null,
    "headline": "OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee",
    "summary": "PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of exper",
    "url": "https://finnhub.io/api/news?id=56a2cd300fa15444a22165738435fe91c407f8972b055d22953fa5dddf2e5548",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754478000,
      "headline": "OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee",
      "id": 136232363,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "PRESS RELEASE OMass Therapeutics Appoints Carol A. Schafer as Non-Executive Director and Chair of the Audit Committee Oxford, United Kingdom – 6th August 2025 – OMass Therapeutics (‘OMass’ or ‘the Company’), a biotechnology company identifying medicines against highly validated target ecosystems such as membrane proteins or intracellular complexes, today announces the appointment of Carol A. Schafer as non-executive Director and Chair of the Audit Committee. Carol has more than 25 years of exper",
      "url": "https://finnhub.io/api/news?id=56a2cd300fa15444a22165738435fe91c407f8972b055d22953fa5dddf2e5548"
    }
  },
  {
    "ts": null,
    "headline": "Why I Still Don't Think Amgen Is A Buy",
    "summary": "Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline.",
    "url": "https://finnhub.io/api/news?id=736a8a9e70608336a8a919ce1b01697fb78959773b9cd0549c4dbfdb542b6b19",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754477796,
      "headline": "Why I Still Don't Think Amgen Is A Buy",
      "id": 136237192,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1323875427/image_1323875427.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen delivered strong Q2 2025 results, beating expectations and raising full-year guidance, driven by robust growth in key products despite Enbrel's decline.",
      "url": "https://finnhub.io/api/news?id=736a8a9e70608336a8a919ce1b01697fb78959773b9cd0549c4dbfdb542b6b19"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Wednesday: AMD, Super Micro, Rivian",
    "summary": "↘️ Advanced Micro Devices (AMD): The chip maker's quarterly adjusted earnings met expectations, while revenue beat forecasts. However, the stock slipped 4.5% in premarket trading. ↘️ Snap (SNAP): The company behind Snapchat reported a wider quarterly loss and missed sales expectations after a problem with its advertising platform.",
    "url": "https://finnhub.io/api/news?id=f15a2299db71cc04fd4dc89afc69ca4fec1d6860f2235801cb36c8d359ba4100",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754474039,
      "headline": "Stocks to Watch Wednesday: AMD, Super Micro, Rivian",
      "id": 136232260,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "↘️ Advanced Micro Devices (AMD): The chip maker's quarterly adjusted earnings met expectations, while revenue beat forecasts. However, the stock slipped 4.5% in premarket trading. ↘️ Snap (SNAP): The company behind Snapchat reported a wider quarterly loss and missed sales expectations after a problem with its advertising platform.",
      "url": "https://finnhub.io/api/news?id=f15a2299db71cc04fd4dc89afc69ca4fec1d6860f2235801cb36c8d359ba4100"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...",
    "summary": "Amgen Inc (AMGN) reports a 9% revenue increase and advances its diverse portfolio with significant sales growth across key products.",
    "url": "https://finnhub.io/api/news?id=ac0489ce5f0afd9d3bb22e0821e65846d98839ab57f5057eaf08f62bc2e27e52",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754465186,
      "headline": "Amgen Inc (AMGN) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and Robust Pipeline ...",
      "id": 136232365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc (AMGN) reports a 9% revenue increase and advances its diverse portfolio with significant sales growth across key products.",
      "url": "https://finnhub.io/api/news?id=ac0489ce5f0afd9d3bb22e0821e65846d98839ab57f5057eaf08f62bc2e27e52"
    }
  }
]